Potential serotonergic agents for the treatment of schizophrenia (Q38635792)

5 September 2017

title

Potential serotonergic agents for the treatment of schizophrenia (English)

1 reference

5 September 2017

1 reference

6

Pierre-Michel Llorca

1 reference

5 September 2017

4

Ludovic Samalin

1 reference

5 September 2017

2

Michel Bourin

1 reference

5 September 2017

Ricardo P Garay

1

1 reference

5 September 2017

Evelyne de Paillette

series ordinal

3

1 reference

5 September 2017

Ahcène Hameg

series ordinal

5

1 reference

5 September 2017

language of work or name

English

0 references

publication date

17 November 2015

1 reference

Expert Opinion on Investigational Drugs

5 September 2017

published in

1 reference

5 September 2017

volume

25

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

159-170

1 reference

Definition and description of schizophrenia in the DSM-5

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Physical illness and schizophrenia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The role of serotonin receptors in the action of atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

5-HT(2C) agonists as therapeutics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The effect of Ondansetron on memory in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The role of ondansetron in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

5-HT6 receptors: a novel target for cognitive enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Investigational drugs for anxiety in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Idalopirdine as a treatment for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Inverse agonism and its therapeutic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Pimavanserin for the treatment of Parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Combination of escitalopram and a 5-HT(₁A) receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT(₂C) receptor stimulation; suggestive of antipsychotic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The 5-HT3 receptor--the relationship between structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Anti-anxiety effect of a novel 5-HT₃ receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

5‐HT6 receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Genetic animal models: focus on schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Animal models of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Cloning and characterisation of the human 5-HT5A serotonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

5-ht5A receptors as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Functional, molecular and pharmacological advances in 5-HT7 receptor research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Remission in schizophrenia: proposed criteria and rationale for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Executive functioning in schizophrenia: Unique and shared variance with measures of fluid intelligence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

Idalopirdine for Alzheimer's disease: written in the stars.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1121995

10.1517/13543784.2016.1121995

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ulu6n5mhyvd2lhb4uytaclu2yu

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_ulu6n5mhyvd2lhb4uytaclu2yu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ulu6n5mhyvd2lhb4uytaclu2yu

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/ulu6n5mhyvd2lhb4uytaclu2yu

1 reference